ATAI - Company ID 0001840904
The table below shows ATAI Life Sciences N.V.'s cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Operating cash flow | -$82.44M | -$84.12M | -$104.47M | -$63.25M | -$20.77M |
| Capital expenditure | $6.00K | $259.00K | $773.00K | $173.00K | $59.00K |
| Investing cash flow | $59.17M | -$53.30M | -$86.85M | -$81.28M | -$28.27M |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - |
ATAI Life Sciences N.V. reported operating cash flow of -$82.44M for fiscal year 2024. That is up 2.0% from -$84.12M in fiscal 2023. Over the 5 fiscal years shown, operating cash flow declined from -$20.77M (FY 2020) to -$82.44M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| $500.00K |
| - |
| Financing cash flow | $5.37M | -$8.36M | $20.79M | $409.86M | $113.05M |